Moreover, the predictability of RAS blockade usage was reduced but near significant (adjusted OR, 0.65; 95% CI, 0.39–1.08) after adjustment for gender, age, CKD stage, observation time, DM, hypertension, CAD, antilipid agent use and the levels of albumin, Hct, and UPCR. The gene discussed is ALB; the disease is chronic kidney disease.